NYSE:ATI
ATI INC
ATI Inc. develops and markets premium medical imaging solutions that drive diagnostic precision for healthcare providers globally.
Key Metrics
Investment Thesis
Bull Case
ATI offers an attractive investment case due to its dominant position in high-margin premium imaging segments with excellent service attach rates, a robust balance sheet holding over $416M in cash that funds growth without excessive debt, and consistent revenue growth driven by both system replacements and new hospital installations.
Bear Case
The stock faces headwinds from elevated interest rates increasing the cost of capital for hospital buyers and potential market saturation in mature regions like North America, alongside significant investment outflows of $234.5M in investing activities that could pressure short-term liquidity if capital returns are constrained.
About ATI INC
ATI Inc. is a global provider of advanced medical imaging technologies, primarily serving hospitals, diagnostic centers, and research institutions worldwide. The company designs and manufactures high-end systems such as the Discovery CT and PET/CT scanners that enable precise patient diagnosis and treatment planning. With operations spanning North America, Europe, and Asia, ATI leverages its proprietary technology to capture significant market share in the competitive medical equipment sector.
Analysis
Management Discussion
Management demonstrated resilience with revenue growing 6% year-over-year to $4.59B while net income recovered strongly to $418.6M, reversing previous declines. Strong operating cash flow of $614.3M allowed the company to return significant capital to shareholders through $470M in share repurchases despite heavy investing outflows for R&D and expansion.
Industry Overview
The medical imaging industry is a high-growth sector fueled by an aging population, rising prevalence of chronic diseases, and the shift toward preventive care requiring advanced diagnostics. While competition from lower-cost alternatives exists, the demand for high-end, AI-enhanced imaging systems remains robust as healthcare providers prioritize diagnostic accuracy over pure cost savings.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $3.84B | $4.17B | $4.36B | $4.59B |
| Cost of Revenue | $3.12B | $3.37B | $3.46B | $3.58B |
| Gross Profit | $714.2M | $802.6M | $898.2M | $1.01B |
| Operating Expenses | $426.9M | $336.2M | $289.3M | $366.1M |
| Operating Income | $287.3M | $466.4M | $608.9M | $640.9M |
| R&D | $16.3M | $20.7M | $19.6M | $21.3M |
| G&A | $297.5M | $328.1M | $342.3M | $365.1M |
| Stock-Based Comp | $26.0M | $29.1M | $34.1M | $29.0M |
| D&A | $142.9M | $146.1M | $151.5M | $168.1M |
| Depreciation | — | — | — | $146.6M |
| Amortization | $8.0M | $7.0M | $7.0M | $7.0M |
| Other OpEx | $113.1M | $-12.6M | $-72.6M | $-20.3M |
| Non-Operating Income | $-125.3M | $-171.2M | $-122.8M | $-118.6M |
| Interest Income | $4.7M | $13.0M | $16.0M | $12.1M |
| Pre-Tax Income | $162.0M | $295.2M | $486.1M | $522.3M |
| Income Tax | $15.5M | $-128.2M | $103.4M | $103.7M |
| Continuing Ops | $130.9M | $410.8M | $367.8M | $418.6M |
| Discontinued Ops | $15.6M | $12.6M | $14.9M | $0 |
| Net Income | $146.5M | $423.4M | $382.7M | $418.6M |
| Minority Interest | $15.6M | $12.6M | $14.9M | $14.3M |
| Net to Common | $130.9M | $410.8M | $367.8M | $404.3M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $2.48B | $2.74B | $2.94B | $2.68B |
| Cash & Equivalents | $584.0M | $743.9M | $721.2M | $416.7M |
| Accounts Receivable | $579.2M | $625.0M | $709.2M | $686.1M |
| Inventory | $1.20B | $1.25B | $1.35B | $1.40B |
| Other Current Assets | $117.5M | $121.3M | $161.6M | $174.0M |
| Long-Term Assets | $1.97B | $2.25B | $2.29B | $2.42B |
| PP&E (Net) | $1.55B | $1.67B | $1.78B | $1.94B |
| Goodwill | $227.2M | $227.2M | $227.2M | $225.2M |
| Other LT Assets | $192.9M | $354.3M | $281.5M | $253.8M |
| Total Assets | $4.45B | $4.99B | $5.23B | $5.10B |
| Current Liabilities | $963.9M | $977.1M | $1.21B | $1.01B |
| Accounts Payable | $553.3M | $524.8M | $609.1M | $568.2M |
| Deferred Revenue | $149.1M | $163.6M | $169.4M | $146.4M |
| Other Current Liab | $261.5M | $288.7M | $430.0M | $291.7M |
| Long-Term Liabilities | $2.32B | $2.53B | $2.07B | $2.18B |
| Other LT Liab | $2.26B | $2.49B | $2.02B | $2.09B |
| Total Liabilities | $3.29B | $3.50B | $3.28B | $3.18B |
| Shareholders' Equity | $1.16B | $1.48B | $1.96B | $1.92B |
| Retained Earnings | $176.9M | $-70.1M | $64.3M | $468.7M |
| AOCI | $-725.2M | $-83.2M | $-89.5M | $-60.4M |
| Treasury Stock | $87.0M | $184.0M | $82.6M | $502.7M |
| Total L&E | $4.45B | $4.99B | $5.23B | $5.10B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $146.5M | $423.4M | $382.7M | $418.6M |
| Non-Cash Adjustments | $-375.9M | $-481.4M | $-337.8M | $260.2M |
| Working Capital Changes | $454.3M | $143.9M | $362.3M | $-64.5M |
| Cash from Operations | $224.9M | $85.9M | $407.2M | $614.3M |
| Cash from Investing | $-126.7M | $-193.2M | $-159.6M | $-234.5M |
| Debt Issuances | $0 | $425.0M | $0 | $0 |
| Share Buybacks | $139.9M | $85.2M | $260.0M | $470.0M |
| Cash from Financing | $-201.9M | $267.2M | $-260.4M | $-699.9M |
| FX Effect | $0 | $0 | $-7.6M | $15.6M |
| Net Change in Cash | $-103.7M | $159.9M | $-22.7M | $-304.5M |
| Beginning Cash | $687.7M | $584.0M | $743.9M | $721.2M |
| Ending Cash | $584.0M | $743.9M | $721.2M | $416.7M |
Frequently Asked Questions
How does ATI INC make money?
The company's revenue is driven by three core segments: Medical Imaging Systems which includes CT, MRI, and PET/CT hardware sales; Service and Parts providing maintenance contracts and replacement components to existing device owners; and Information Technology offering specialized software and IT support services for hospital imaging networks.
What are the main risks for ATI?
Investors should consider the risk of intense price competition from Japanese and Korean rivals like Canon and Toshiba, potential supply chain disruptions affecting rare earth elements used in magnets, regulatory delays related to FDA or CE approvals for new product launches, and macroeconomic headwinds that may delay hospital capital expenditure on expensive imaging equipment.
What is ATI's competitive advantage?
ATI maintains a robust competitive moat through its patented image reconstruction algorithms that produce superior diagnostic quality at lower radiation doses, a strong installed base of legacy devices ensuring recurring service revenue, and a highly responsive global service network that minimizes equipment downtime for clients.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.